Reuters logo
9 个月前
BRIEF-Atara Bio receives positive opinion from EMA on orphan drug designation for its CMV-CTL product candidate
2016年10月11日 / 中午12点12分 / 9 个月前

BRIEF-Atara Bio receives positive opinion from EMA on orphan drug designation for its CMV-CTL product candidate

1 分钟阅读

Oct 11 (Reuters) - Atara Biotherapeutics Inc

* Atara Bio receives positive opinion from EMA on orphan drug designation for allogeneic cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) for treatment of CMV infection in patients with impaired immune systems Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below